November 23, 2018

ASH 2018: Dec 1-4

Please join our staff as we participate or present in the following presentations at the 2018 ASH Annual Meeting

18-CNR-4455 QD ASH

Friday Satellite Symposium
Friday, Nov. 30
Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies
Chair and Speaker: Matt Kalaycio, MD
7–11 a.m.
Hyatt, Coronado Ballroom A-C

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

What’s New in VTE? Evaluating the Latest Evidence and Grades of Recommendation
Chair: Alok Khorana, MD
12:30–4:30 p.m.
Hyatt, Coronado Ballroom A-C

Friday Scientific Workshops
Friday, Nov. 30
Ethical Discussion Surrounding Testing
Panelist: Hetty E. Carraway, MD, MBA
4:30–5:15 p.m.
San Diego Convention Center, Room 28D

Special Scientific Symposium
Monday, Dec. 3
Special Symposium on the Basic Science of Hemostasis and Thrombosis
Co-Chair: Keith R. McCrae, MD
4:30–6:30 p.m.
San Diego Convention Center, Room 30D

Best of ASH in Hemostasis and Thrombosis 2
Speaker: Keith R. McCrae, MD
4:30–6:30 p.m.
San Diego Convention Center, Room 30D

Education Programs
2018 Education Program Co-Chair: Mikkael A. Sekeres, MD

Sessions on Malignant Hematology
Saturday, Dec. 1
The Molecular Maelstrom of Myelodysplastic Syndromes (MDS): The MDS Genomics-Prognosis Symbiosis
Speaker: Aziz Nazha, MD
4:00–5:30 p.m.
San Diego Convention Center, Room 6A

Sunday, Dec. 2
Reining in Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation:
Current Approaches to Prevent and Treat GVHD Following Allogeneic Stem Cell Transplantation
Speaker: Betty K. Hamilton, MD
7:30–9:00 a.m.
Manchester Grand Hyatt San Diego, Grand Hall D

The Molecular Maelstrom of Myelodysplastic Syndromes (MDS): The MDS Genomics-Prognosis Symbiosis
Speaker: Aziz Nazha, MD
9:30–11:00 a.m.
San Diego Convention Center, Room 6A

Using Genomics to Risk Stratify and Treat Kids: Ethical Conundrums in Pediatric Genomics
Speaker: Eric Kodish, MD
9:30–11:00 a.m.
Marriott Marquis San Diego Marina, San Diego Ballroom B

Monday, Dec. 3
Using Genomics to Risk Stratify and Treat Kids: Ethical Conundrums in Pediatric Genomics
Speaker: Eric Kodish, MD
7:00–8:30 a.m.
Marriott Marquis San Diego Marina, Pacific Ballroom 21

Reining in Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation:
Current Approaches to Prevent and Treat GVHD Following Allogeneic Stem Cell Transplantation
Speaker: Betty K. Hamilton, MD
10:30 a.m.–Noon
Manchester Grand Hyatt San Diego, Grand Hall D

Education Spotlight Sessions
Sunday, Dec. 2
Population Risks of Developing Myeloid Malignancies
Chair: Sudipto Mukherjee, MD, PhD, MPH
4:30–6:00 p.m.
San Diego Convention Center, Room 11B

From Fat Man to Agent Orange and Beyond: When Myeloid Malignancies Strike
Speaker: Sudipto Mukherjee, MD, PhD, MPH
4:30–6:00 p.m.
San Diego Convention Center, Room 11B

Monday, Dec. 3
The Story Is the Story: Using Narrative Medicine to Cure Disease
Chair: Mikkael A. Sekeres, MD, MS
10:30 a.m.–Noon
San Diego Convention Center, Room 6E

Scientific Programs
Saturday, Dec. 1
Scientific Committee on Thrombosis and Vascular Biology
Microparticles and Exosomes: Ready for the Clinic?
Chair: Keith R. McCrae, MD
9:30–11:00 a.m.
San Diego Convention Center, Room 24B
Or
4:00–5:30 p.m.
San Diego Convention Center, Room 11B

Monday, Dec. 3
Special Scientific Symposia
Special Symposium on the Basic Science of Hemostasis and Thrombosis
Co-Chair: Keith R. McCrae, MD
4:30–6:30 p.m.
San Diego Convention Center, Room 30D

Best of ASH in Hemostasis and Thrombosis 2
Speaker: Keith R. McCrae, MD
4:30–6:30 p.m.
San Diego Convention Center, Room 30D

Special Interest Sessions
Friday, Nov. 30
Training Program Directors’ Workshop
Chair: Hetty E. Carraway, MD, MBA
11 a.m.–2 p.m.
Petco Park, The Auditorium

Sunday, Dec. 2
Social Media for the Hematologist: Today and in the Future
Chair: Aaron T. Gerds, MD, MS
11:15 a.m.–12:15 p.m.
San Diego Convention Center, Room 28D

Trainee Activities
Friday, Nov. 30
Blood Drops. Career 101: Early Career Planning Topics
Knocking Your Fellowship Interview out of the Park! Tips to Make Sure Your Interview Day Is a #homerun
Speaker: Hetty E. Carraway, MD, MBA
1:30–4:45 p.m.
Petco Park, Western Metal Concourse

Blood Drops. Hematology 201: A Mid-Level Clinical Topic
Identifying White Cell Disorder on the Peripheral Smear
Speaker: Anne T. Neff, MD
1:30–4:45 p.m.
Petco Park, Western Metal Concourse

Blood Drops. Wellness: Topics to Help Your Well-Being
Telling It Like It Is — Essays About Medicine
Speaker: Mikkael A. Sekeres, MD, MS
1:30–4:45 p.m.
Petco Park, Western Metal Concourse

Blood Buddies. Mentor Session 1
Adult Clinical Non-Malignant Hem
Presenter: Keith R. McCrae, MD
2:30–3:00 p.m.
Petco Park, Section 124 — The Porch

Laboratory & Translational Hem
Presenter: Keith R. McCrae, MD
2:30–3:00 p.m.
Petco Park, Section 124 — The Porch

Adult Clinical Malignant Hem
Presenter: Aziz Nazha, MD
2:30–3:00 p.m.
Petco Park, Section 124 — The Porch

Blood Buddies. Mentor Session 2
Laboratory & Translational Hem
Presenter: Keith R. McCrae, MD
3:30–4:00 p.m.
Petco Park, Section 124 — The Porch

Adult Clinical Non-Malignant Hem
Presenter: Keith R. McCrae, MD
3:30–4:00 p.m.
Petco Park, Section 124 — The Porch

Adult Clinical Malignant Hem
Presenter: Aziz Nazha, MD
3:30–4:00 p.m.
Petco Park, Section 124 — The Porch

Saturday, Dec. 1
Career-Development Lunch Sessions
Adult Clinical Malignant Hematology/BMT
Speaker: Navneet Majhail, MD
11:15 a.m.–12:15 p.m.
Hilton San Diego Bayfront, Sapphire Ballroom AB

General Sessions
Tuesday, Dec. 4
Late-Breaking Abstracts
Hematology Disease Topics & Pathways: Biological Processes
Co-Chair: Mikkael A. Sekeres, MD, MS
7:30–9:00 a.m.
San Diego Convention Center, Hall AB

Plenary Scientific Sessions
Sunday, Dec. 2
Hematology Disease Topics & Pathways: Biological, Diseases, MDS, Myeloid Malignancies
1 The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
Co-Author: Mikkael A. Sekeres, MD, MS
2–4 p.m.
San Diego Convention Center, Hall AB

Late Breaking Abstract Sessions
Tuesday, Dec 4
LBA-1 Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)
Presenter: Alok Khorana, MD
7:30 a.m.
San Diego Convention Center, Hall AB

Oral Sessions
Saturday, Dec. 1
Session 614. Acute Lymphoblastic Leukemia: Therapy, Excluding Transplantation: Improving Frontline Therapy in ALL
33 Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed by Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia
Presenter: Anjali S. Advani, MD
8 a.m.
Marriott Marquis San Diego Marina, Pacific Ballroom 20

Session 615. Acute Myeloid Leukemia: Commercially Available Therapy, Excluding Transplantation: Optimal Induction and Re-Induction Regimens for Acute Myeloid Leukemia
Moderator: Anjali S. Advani, MD
9:30–11:00 a.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom F

Session 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Outcomes with CD19 CAR T Therapy and Checkpoint Blockade in the Real-World Setting
Moderator: Brian T. Hill, MD, PhD
9:30–11:00 a.m.
Marriott Marquis San Diego Marina, Pacific Ballroom 20

91 Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real-World Experience
Co-Author: Brian T. Hill, MD, PhD
9:30 a.m.

104 Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS)
Presenter: Yasunobu Nagata
Co-Authors: Cassandra M. Hirsch; Abhinav Goyal; Hassan Awada, MD; Mohammad Fahad B. Asad; Teodora Kuzmanovic, BA; Bartlomiej P. Przychodzen; Sudipto Mukherjee, MD, PhD, MPH; Tomas Radivoyevitch, PhD; Aziz Nazha, MD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD
9:45 a.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom A

107 SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition
Co-Authors: Bartlomiej Przychodzen; Jaroslaw P. Maciejewski, MD, PhD
10:30 a.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom A

108 Novel and Significant Impact of Germline Variants Predisposed to Pathogenic Somatic Mutations and Loss of Heterozygosity (LOH) in Myelodysplastic Syndromes (MDS) and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Co-Author: Yasunobu Nagata
10:45 a.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom A

Session 802. Chemical Biology and Experimental Therapeutics: New Targeted Therapies and Drug Development
211 Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies
Presenter: Valeria Visconte, PhD
Co-Authors: Bartlomiej P. Przychodzen; Vera Adema, PhD; Cassandra M. Hirsch; Allison Noe; Rachel Toth; Christina Snider, BA; Hassan Awada, MD; Amy C Graham, BS, MS; Yvonne Parker; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Tomas Radivoyevitch; Heesun J. Rogers, MD, PhD; Daniel Lindner, MD, PhD; Richard A. Padgett; Mikkael A. Sekeres, MD, MS; James G. Phillips, PhD; Jaroslaw P. Maciejewski, MD, PhD
2 p.m.
San Diego Convention Center, Room 7B

216 A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis
Presenter: Ashwin Kishtagari, MBBS
Co-Authors: Kwok Peng Ng, PhD; Charlotte Jarman; Anand D. Tiwari, PhD; James G. Phillips, PhD; Caroline Schuerger; Babal K. Jha; Yogenthiran Saunthararajah, MD
3:15 p.m.
San Diego Convention Center, Room 7B

Session 732. Clinical Allogeneic Transplantation: Results: To Transplant or Not to Transplant? That Is the Question
206 A Personalized Prediction Model for Outcomes After Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee
Presenter: Aziz Nazha, MD
Co-Authors: Betty K. Hamilton, MD; Navneet S. Majhail, MD, MS; Ronald Sobecks, MD
2:15 p.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom A

207 Survival Differences Among Patients with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study
Co-Authors: Aaron T. Gerds, MD, MS; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MP
2:30 p.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom A

Sunday, Dec. 2
Session 732. Clinical Allogeneic Transplantation: Results: Optimizing Outcomes After Allogeneic Transplantation
308 Related and Unrelated Donor Transplantation for β Thalassemia Major: Results of an International Survey
Co-Author: Rabi Hanna, MD
7:45 a.m.
Manchester Grand Hyatt San Diego, Grand Hall A

Session 113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Sickle Cell Disease—Role of Coagulation and Inflammation in Pathophysiology
268 High Molecular Weight Kininogen Contributes to End-Organ Damage and Mortality in a Mouse Model of Sickle Cell Disease
Co-Author: Keith R. McCrae, MD
8:15 a.m.
San Diego Convention Center, Room 33B

Session 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Combination Therapy
331 Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative and Subgroup Analyses Clinically Relevant Abstract
Co-Author: Anjali S. Advani, MD
9:30 a.m.
Manchester Grand Hyatt San Diego, Grand Hall B

Session 634. Myeloproliferative Syndromes: Clinical: Addressing Areas of Unmet Need in Prognostic Assessments and Therapy for MPNs
353 A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis
Co-Author: Aaron T. Gerds, MD, MS
10:30 a.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom F

Session 904. Outcomes Research—Malignant Conditions: Outcomes in Myeloid Malignancies and Allogeneic Stem Cell Transplant
371 Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States
Presenter: Raffi Tchekmedyian, BS
Co-Authors: Tomas Radivoyevitch, PhD; Aaron T. Gerds, MD, MS; Aziz Nazha; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Jaroslaw P. Maciejewski; Matt Kalaycio, MD; Navneet S. Majhail, MD, MS; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH
10:30 a.m.
San Diego Convention Center, Room 25B

Session 901. Health Services Research—Non-Malignant Conditions: Thrombosis and Anticoagulation
366 Economic Burden of Venous Thromboembolism in Cancer Patients — a Comparative Analysis Between Matched Patients with Cancer with and without a Diagnosis of Venous Thromboembolism
Co-Author: Alok A. Khorana, MD
10:45 a.m.
San Diego Convention Center, Room 8

Session 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: New Agents
397 Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study
Co-Authors: Deepa Jagadeesh, MD, MPH; Robert M. Dean, MD; Brad Pohlman, MD; Sarah L. Ondrejka, DO; Eric D. Hsi, MD; Brian T. Hill, MD, PhD
Noon
Marriott Marquis San Diego Marina, Pacific Ballroom 20

Session 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Population Based Outcomes in Aggressive Lymphoma
451 Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 U.S. Academic Centers
Co-Authors: Sarah S. Lee, MD; Brian T. Hill, MD, PhD
4:30 p.m.
San Diego Convention Center, Ballroom 20D

453 Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy
Co-Author: Brian T. Hill, MD, PhD
5 p.m.
San Diego Convention Center, Ballroom 20D

455 Outcomes of Patients with Relapsed/Refractory Double Expressor B Cell Lymphoma as Defined by Multicenter Pathology Review Treated with Ibrutinib Monotherapy
Co-Authors: Allison M. Winter, MD; Brian T. Hill, MD, PhD; Sarah L. Ondrejka, DO; Eric D. Hsi, MD 5:30 p.m.
San Diego Convention Center, Ballroom 20D

Session 637. Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics II
466 PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: an Initial Safety and Efficacy Analysis
Presenter: Aaron T. Gerds, MD, MS
5:15 p.m.
Manchester Grand Hyatt San Diego, Grand Hall A

Session 332. Antithrombotic Therapy: Management of Challenging Patients and Scenarios
425 Heparin vs Direct Thrombin Inhibitors in Patients with Previous HIT Undergoing Cardiothoracic Surgery: the Cleveland Clinic Experience
Presenter: Daniel S. Carlson, DO
Co-Author: Keith R. McCrae, MD
5:30 p.m.
San Diego Convention Center, Room 33B

Monday, Dec. 3
Session 634. Myeloproliferative Syndromes: Clinical: Interferon Therapy and Mutational Analysis in the MPNs
Moderator: Aaron T. Gerds, MD, MS
7:00–8:30 a.m.
Manchester Grand Hyatt San Diego, Grand Hall D

Session 508. Bone Marrow Failure: Acquired Bone Marrow Failure and Somatic Genetics
537 Next-Generation Sequencing Reveals a T Cell Receptor Signature Characteristic of Patients with Aplastic Anemia
Co-Authors: Cassandra M. Hirsch; Jaroslaw P. Maciejewski, MD, PhD
7:30 a.m.
Marriott Marquis San Diego Marina, Grand Ballroom 2

Session 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, Including HIV and Other Infections: B and T Cell Biology
516 Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance
Presenter: Cassandra M. Hirsch
Co-Authors: Michael Clemente, MS; Peter Chomczynski; Bartlomiej P. Przychodzen; Yasunobu Nagata; Vera Adema, PhD; Louis Williams, MD, MBA; Valeria Visconte, PhD; Alan Lichtin, MD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD
8:15 a.m.
San Diego Convention Center, Room 8

Session 703. Adoptive Immunotherapy: In Vitro, Correlative, and Early Phase Studies to Improve Safety and Efficacy of CAR-T Cells
697 Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR
Co-Author: Robert M. Dean, MD
10:30 a.m.
Marriott Marquis San Diego Marina, San Diego Ballroom B

Session 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Therapy of Post-Transplantation Relapse
704 Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival After Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation
Co-Author: Ronald Sobecks, MD
10:45 a.m.
Manchester Grand Hyatt San Diego, Grand Hall B

Session 902. Health Services Research—Malignant Diseases: Big Data and Outcomes Research
712 Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety
Presenter: Madeline Waldron, PharmD
Co-Authors: Caitlin Siebenaller, PharmD; Marc Earl, PharmD; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Aziz Nazha, MD; Aaron T. Gerds, MD, MS; Betty K. Hamilton, MD; Ronald Sobecks, MD; Matt Kalaycio, MD; Barb Tripp, CNS; Brian P. Hobbs, PhD; Sudipto Mukherjee, MD, PhD, MPH; and Mikkael A. Sekeres, MD, MS
11:15 a.m.
San Diego Convention Center, Room 24B

Session 637. Myelodysplastic Syndromes—Clinical Studies: Prognosis and Prediction
793 A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes
Presenter: Aziz Nazha, MD
Co-Authors: Sudipto Mukherjee, MD, PhD, MPH; Yazan F. Madanat, MD; Teodora Kuzmanovic; Cassandra M. Hirsch; Vera Adema, PhD; Jaroslaw P. Maciejewski; Mikkael A. Sekeres, MD, MS
2:45 p.m.
Manchester Grand Hyatt San Diego, Grand Hall A

Advertisement

Session 902. Health Services Research—Malignant Diseases: Population Studies, End-of-life and Palliative Care
Moderator: Navneet S. Majhail, MD, MS
2:45–4:15 p.m.
San Diego Convention Center, Room 24B

Session 902. Health Services Research—Malignant Diseases: Quality Of Life Studies
Moderator: Betty K. Hamilton, MD
4:30–6:00 p.m.
San Diego Convention Center, Room 24B
Session 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches

929 Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach
Co-Author: Eric D. Hsi, MD
5:30 p.m.
San Diego Convention Center, Room 6F

Session 612. Acute Lymphoblastic Leukemia: Clinical Studies: Improving Outcomes with Cellular Therapy
900 Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?
Presenter: Remco J. Molenaar, MD, PhD
Co-Authors: Tomas Radivoyevitch; Aaron T. Gerds, MD, MS; Aziz Nazha, MD; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Matt Kalaycio, MD; Navneet S. Majhail, MD, MS; Jaroslaw P. Maciejewski; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH
5:45 p.m.
San Diego Convention Center, Room 6A

Session 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity and Novel Approaches with Targeted Therapy
1015 T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes
Co-Authors: Sagar S. Patel, MD
6:15 p.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom A

Poster Sessions
Saturday, Dec. 1
6:15–8:15 p.m.
San Diego Convention Center, Hall GH

Session 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster I
1038 Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry
Co-Author: Jaroslaw P. Maciejewski

Session 112. Thalassemia and Globin Gene Regulation: Poster I
1054 The LSD1 Inhibitor RN-1 Increases Gamma-Globin Expression in Baboons by Targeting an Early Event Responsible for Gamma-Globin Repression
Co-Author: Yogenthiran Saunthararajah, MD

Session 331. Pathophysiology of Thrombosis: Poster I
1226 Expression of Recombinant β2GPI and Site-Directed Mutants Provides Insight into the Pathogenesis of Antiphospholipid Syndrome
Presenter: Ravi Kumar Alluri, PhD
Co-Authors: Suman Kundu, MBA; Keith R. McCrae, MD

Session 332. Antithrombotic Therapy: Poster I
1237 Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism
Presenter: Deborah Y. Park, BS
Co-Authors: Shyam K. Poudel, MD; Xuefei Jia, MS; Mailey Lynn Wilks, CNP, MSN, APRN; Vicki Pinkava, MSBS, PA-C; Meghan O’Brien, MS, ANP-BC; Barbara Tripp, CNS, AOCN; Jung-Min Song, RN, CNS; Keith R. McCrae, MD; Dana E. Angelini, MD; Alok A. Khorana, MD

1242 Outcomes Associated with Therapeutic Anticoagulation in Patients with Brain Metastasis
Presenter: Shafia Rahman, MD,
Co-Authors: Fahrettin Covut, MD, Yihong Zhou, MD, Shab E Gul Rahim, MD, Sudha Amarnath, MD, Alok A. Khorana, MD

Session 508. Bone Marrow Failure: Poster I
1302 Novel Small Molecule Stimulants of Hematopoietic Stem Cells and Their Mode of Action
Presenter: Sergei Vatolin, PhD
Co-Author: Jaroslaw P. Maciejewski, MD, PhD

1303 Selective Pharmacologic Inhibition of Paroxysmal Nocturnal Hemoglobinuria Clones
Presenter: Amy C. Graham, BS, MS
Co-Authors: Alexey Efanov, PhD; Bartlomiej P. Przychodzen; Cassandra M. Hirsch; Vera Adema, PhD; Valeria Visconte, PhD; Jaroslaw P. Maciejewski, MD, PhD

Session 613. Acute Myeloid Leukemia: Clinical Studies: Poster I
1388 Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: a Large Multi-Center Prospective Longitudinal Observational Study
Co-Authors: Aaron T. Gerds, MD, MS; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

1389 Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations After Intensive Chemotherapy
Co-Authors: Bhumika J. Patel, MD; Hetty E. Carraway, MD, MBA; Teodora Kuzmanovic; Aziz Nazha, MD; Shimoli Vipul Barot, MD; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Sudipto Mukherjee, MD, PhD, MPH; Meghan Scully, NP; Aaron T. Gerds, MD, MS; Anjali S. Advani, MD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

Session 615. Acute Myeloid Leukemia: Commercially Available Therapy, Excluding Transplantation: Poster I
1428 Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: an Analysis from a Large International Patient Cohort
Co-Authors: Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

Session 617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I
1491 Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group
Co-Authors: Heesun J. Rogers, MD, PhD; Eric D. Hsi, MD

1527 Differences in Genomic Patterns Between African Americans and Whites with Acute Myeloid Leukemia
Presenter: Rachel Hu, MD
Co-Authors: Aziz Nazha, MD; Xuefei Jia, MS; Brian P. Hobbs, PhD; Hetty E. Carraway, MD, MBA; Sudipto Mukherjee, MD, PhD, MPH; Aaron T. Gerds, MD, MS; Anjali S. Advani, MD; Yasunobu Nagata; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Babal K. Jha; Jaroslaw P. Maciejewski, MD, PhD; Mikkael A. Sekeres, MD, MS

Session 622. Lymphoma Biology—Non-Genetic Studies: Poster I
1591 The Role of High Molecular Weight Kininogen in Lymphoma Microvascular Density and Growth
Presenter: Huseyin Halil Erdemir, MD
Co-Authors: Meenal Shukla, PhD; Keith R. McCrae, MD

Session 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I
1648 Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration
Co-Authors: Allison M. Winter, MD; Brian T. Hill, MD, PhD

Session 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
1677 Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study
Co-Author: Brian T. Hill, MD, PhD

1692 Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Presenter: Brian T. Hill, MD, PhD
Co-Authors: Robert M. Dean, MD; Deepa Jagadeesh, MD, MPH; Alex V. Mejia Garcia, MD; Brad Pohlman, MD; Allison M. Winter, MD; Patrick Collier, MD, PhD; Christopher D’Andrea, PA-C; Ashley Morrison, RN; Sarah Lehmann, RN; Sarah L. Ondrejka, DO; Eric D. Hsi, MD

Session 632. Chronic Myeloid Leukemia: Therapy: Poster I
1737 Cardiovascular Mortality Among CML Patients in the Pre-TKI and TKI Eras: a SEER Analysis 1992–2004
Co-Author: Yaning Zhang, MD

Session 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I
1797 Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
Presenter: Yazan F. Madanat, MD
Co-Authors: Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH; Cassandra M. Hirsch; Yihong Guan; Yasunobu Nagata; Vera Adema, PhD; Metis Hasipek, PhD; Aaron T. Gerds, MD, MS; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Bartlomiej P. Przychodzen; Jaroslaw P. Maciejewski; Babal K. Jha; Aziz Nazha, MD

1801 Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data
Co-Author: Bartlomiej P. Przychodzen; Jaroslaw P. Maciejewski, MD, PhD

1802 Genetic Predisposition to Therapy-Related Myeloid Neoplasm by Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes
Co-Authors: Cassandra M. Hirsch; Jaroslaw P. Maciejewski, MD, PhD

1805 Biallelic TET2 Inactivation in Myeloid Neoplasia: from Clonal Hierarchy to Clinical Phenotypes
Presenter: Hassan Awada, MD
Co-Authors: Yasunobu Nagata; Abhinav Goyal; Mohammad Fahad B. Asad; Bhumika J. Patel, MD; Cassandra M. Hirsch; Teodora Kuzmanovic; Vera Adema, PhD; Mai Aly; Bartlomiej P. Przychodzen; Yihong Guan; Louis Williams, MD, MBA; Aziz Nazha, MD; Mohamed Abazeed, MD, PhD; Mikkael A. Sekeres, MD, MS; Tomas Radivoyevitch; Babal K. Jha; Valeria Visconte, PhD; Jaroslaw P. Maciejewski, MD, PhD

Session 637. Myelodysplastic Syndromes—Clinical Studies: Poster I
1813 Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)
Presenter: C. Beau Hilton, BA
Co-Authors: Mikkael A. Sekeres, MD, MS; Aaron T. Gerds, MD, MS; Yihong Guan; Sudipto Mukherjee, MD, PhD, MPH; Yasunobu Nagata; Metis Hasipek, PhD; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Babal K. Jha; Jaroslaw P. Maciejewski, MD, PhD; Aziz Nazha, MD

1824 Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS)
Presenter: Yasunobu Nagata
Co-Authors: Abhinav Goyal; Inom Mirzaev; Mohammad Fahad B. Asad; Hassan Awada, MD; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Aziz Nazha, MD; Sudipto Mukherjee, MD, PhD, MPH; Mikkael A. Sekeres, MD, MS; Tomas Radivoyevitch, PhD; Jacob Scott, MD; Jaroslaw P. Maciejewski, MD, PhD

1825 Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey
Co-Author: Mikkael A. Sekeres, MD, MS

Session 651. Myeloma: Biology and Pathophysiology, Excluding Therapy: Poster I
1899 Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma
Presenter: Rajshekhar Chakraborty, MBBS
Co-Authors: Lisa Rybicki, MS; Robert M. Dean, MD; Beth M. Faiman, PhD, CNP; Matt Kalaycio, MD; Jack Khouri, MD; Christy J. Samaras, DO; Navneet S. Majhail, MD, MS; Jason Valent, MD

Session 653. Myeloma: Therapy, Excluding Transplantation: Poster I
1948 Efficacy and Toxicity Profile of Ibrutinib Based Regimens for Refractory Multiple Myeloma: A Systematic Review
Co-Author: Faiz Anwer, MD

1949 Promising Clinical Efficacy and Toxicity Profile of Isatuximab Based Regimens for Treatment of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Systematic Review
Co-Author: Faiz Anwer, MD

1950 Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: a Systematic Review of Early Clinical Data
Co-Author: Faiz Anwer, MD

1951 Presentation Patterns and Management Strategies for Central Nervous System Involvement in Multiple Myeloma: a Systematic Review of Literature
Co-Author: Faiz Anwer, MD

1952 Evidence Based Recommendations for Supportive Care in Multiple Myeloma
Co-Author: Faiz Anwer, MD

1962 Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide
Co-Author: Jason Valent, MD

2009 Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis
Presenter: Sarah S. Lee, MD
Co-Author: Nathaniel Rosko, PharmD; Bhumika J. Patel, MD; Madeline Waldron, PharmD; Jackie Tomer, MPH; Roman Goldman, CNP; Mary Ann Karam, RN; Janice Reed, RN; Beth M. Faiman, PhD, CNP; Kimberly Hamilton, APRN/PA; Saveta Mathur, CNP; Christy J. Samaras, DO; and Jason Valent, MD

2012 Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
Co-Author: Christy J. Samaras, DO

2022 Pomalidomide Based Regimens for Treatment of Relapsed Multiple Myeloma: a Systematic Review and Meta-Analysis of Clinical Trials
Co-Author: Faiz Anwer, MD

2025 Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: a Systematic Review
Co-Author: Faiz Anwer, MD

Session 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster I
2075 Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia
Presenter: Sagar S. Patel, MD
Co-Authors: Betty K. Hamilton, MD; Lisa Rybicki, MS; Dawn Thomas; Arden Emrick; Aziz Nazha; Sudipto Mukherjee, MD, PhD, MPH; Anjali S. Advani, MD; Hetty E. Carraway, MD, MBA; Brad Pohlman, MD; Brian J. Bolwell, MD; Robert M. Dean, MD; Aaron T. Gerds, MD, MS; Rabi Hanna, MD; Matt Kalaycio, MD; Aiwen Zhang, PhD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD; Navneet S. Majhail, MD, MS; Ronald Sobecks, MD

Session 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
2123 Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution After Nicotinamide-Expanded Cord Blood Transplantation
Co-Author: Rabi Hanna, MD

Session 801. Gene Therapy and Transfer: Poster I
2194 Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases
Co-Author: Faiz Anwer, MD

Session 902. Health Services Research—Malignant Diseases: Poster I
2245 Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: a Systematic Review with a Specific Focus on Geriatric Population
Co-Author: Navneet S. Majhail, MD, MS

2246 Qualitative Study of Factors that Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia
Co-Author: Navneet S. Majhail, MD, MS

2259 Correlation Between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal Study
Co-Author: Aaron T. Gerds, MD, MS

2270 TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer
Presenter: Sophia Colombari Figueroa, BA
Co-Authors: Bhumika J. Patel, MD; Shimoli Vipul Barot, MD; Teodora Kuzmanovic, BA; Aziz Nazha, MD; Eric D. Hsi, MD; James R. Cook, MD, PhD; Sudipto Mukherjee, MD, PhD, MPH; Aaron T. Gerds, MD, MS; Mikkael A. Sekeres, MD, MS; Matt Kalaycio, MD; Anjali S. Advani, MD; Jaroslaw P. Maciejewski, MD, PhD; Hetty E. Carraway, MD, MBA

Session 904. Outcomes Research—Malignant Conditions: Poster I
2298 Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States
Presenter: Raffi Tchekmedyian, BS
Co-Authors: Tomas Radivoyevitch, PhD; Aaron T. Gerds, MD, MS; Aziz Nazha, MD; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Jaroslaw P. Maciejewski, MD, PhD; Matt Kalaycio, MD; Navneet S. Majhail, MD, MS; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

Sunday, Dec. 2
6–8 p.m.
San Diego Convention Center, Hall GH
Session 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II
2330 A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria
Co-Author: Jaroslaw P. Maciejewski, MD, PhD

Session 331. Pathophysiology of Thrombosis: Poster II
2510 Venous Thromboembolism in Cancer Patients Receiving Immunotherapy
Presenter: Joanna Roopkumar, MBBS, MPH
Co-Authors: Ann S. Kim, BA; Thapa Bicky, MD; Brian P. Hobbs, PhD; Alok A. Khorana, MD

Session 503. Clonal Hematopoiesis: Aging and Inflammation: Poster II
2572 Distinct Features of Chip-Derived and De Novo MDS
Presenter: Yasunobu Nagata
Co-Authors: Cassandra M. Hirsch; Hassan Awada, MD; Abhinav Goyal; Teodora Kuzmanovic, BA; Bartlomiej P. Przychodzen; Sudipto Mukherjee, MD, PhD, MPH; Tomas Radivoyevitch, PhD; Aziz Nazha, MD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

Session 508. Bone Marrow Failure: Poster II
2583 Pathogenic Germline Variants in Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH)
Co-Authors: Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Sudipto Mukherjee, MD, PhD, MPH; Hetty E. Carraway, MD, MBA; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

2590 Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia
Presenter: Bhumika J. Patel, MD
Co-Authors: Shimoli Vipul Barot, MD; Teodora Kuzmanovic, BA; Bartlomiej P. Przychodzen; Cassandra M. Hirsch; Hassan Awada, MD; Metis Hasipek, PhD; Swapna Thota, MD; Tomas Radivoyevitch, PhD; Anjali S. Advani, MD; Matt Kalaycio, MD; Mikkael A. Sekeres, MD, MS; Hetty E. Carraway, MD, MBA; Jaroslaw P. Maciejewski, MD, PhD

Session 614. Acute Lymphoblastic Leukemia: Therapy, Excluding Transplantation: Poster II
2699 Comparison of CD22 Expression Between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials
Co-Author: Anjali S. Advani, MD

Session 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Poster II
2732 Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib ‘On Target’ Adverse Events
Co-Author: Mikkael A. Sekeres, MD, MS

2735 Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Co-Author: Mikkael A. Sekeres, MD, MS

Session 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
2809 Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype
Presenter: Aziz Nazha, MD
Co-Authors: Sudipto Mukherjee, MD, PhD, MPH; Ahed Makhoul, MD; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Hetty E. Carraway, MD, MBA; Yasunobu Nagata; Yihong Guan; Teodora Kuzmanovic, BA; Metis Hasipek, PhD; Babal K. Jha; Jaroslaw P. Maciejewski, MD, PhD; Mikkael A. Sekeres, MD, MS

Session 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II
2878 Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration
Co-Author: Eric D. Hsi, MD

2893 Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies
Co-Author: Deepa Jagadeesh, MD, MPH

Session 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

2927 Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: a Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis
Co-Author: Eric D. Hsi, MD

Advertisement

Session 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster II

2967 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Co-Author: Brian T. Hill, MD, PhD

Session 634. Myeloproliferative Syndromes: Clinical: Poster II
3027 Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)
Co-Author: Aaron T. Gerds, MD, MS

Session 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II
3073 LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes
Presenter: Courtney Hershberger, BS
Co-Authors: James Hiznay; Rosemary Dietrich; Xiaorong Gu, PhD; Cassandra M. Hirsch; Amy Graham, BS, MS; Bartlomiej P. Przychodzen; Valeria Visconte, PhD; Vera Adema, PhD; Yvonne Parker; Hetty E. Carraway, MD, MBA; Tomas Radivoyevitch, PhD; Mikkael A. Sekeres, MD, MS; Yogen Saunthararajah, MD; Jaroslaw P. Maciejewski, MD, PhD; Richard A. Padgett

3074 Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS
Presenter: Cassandra M. Hirsch
Co-Authors: Wenyi Shen, MD; Bartlomiej P. Przychodzen; Yasunobu Nagata; Vera Adema, PhD; Teodora Kuzmanovic, BA; Louis Williams, MD, MBA; Aziz Nazha, MD; Valeria Visconte, PhD; Hetty E. Carraway, MD, MBA; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

3084 Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced by Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential
Presenter: Teodora Kuzmanovic
Co-Authors: Bhumika J. Patel, MD; Yasunobu Nagata; Hassan Awada, MD; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Remco J. Molenaar, MD, PhD; Babal K. Jha; Sudipto Mukherjee, MD, PhD, MPH; Anjali S. Advani, MD; Aziz Nazha, MD; Aaron T. Gerds, MD, MS; Hetty E. Carraway, MD, MBA; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD; Tomas Radivoyevitch, PhD

Session 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
3091 Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Co-Author: Mikkael A. Sekeres, MD, MS

3095 Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA
Presenter: Sudipto Mukherjee, MD, PhD, MPH
Co-Authors: Tomas Radivoyevitch, PhD; Brian P. Hobbs, PhD; Xuefei Jia, MS; Jaroslaw P. Maciejewski, MD, PhD; Aziz Nazha, MD; Mikkael A. Sekeres, MD, MS

3096 Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers?
Presenter: Sudipto Mukherjee, MD, PhD, MPH
Co-Authors: Aziz Nazha; Jaroslaw P. Maciejewski, MD, PhD; Mikkael A. Sekeres, MD, MS; Brian P. Hobbs, PhD; Xuefei Jia, MS

3098 What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?
Co-Authors: Aziz Nazha, MD; Mikkael A. Sekeres, MD, MS

3103 Therapy-Related MDS Can Be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS
Co-Author: Mikkael A. Sekeres, MD, MS

Session 642. CLL: Therapy, Excluding Transplantation: Poster II
3142 Venetoclax as Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients
Co-Authors: Brian T. Hill, MD, PhD; Allison M. Winter, MD

Session 653. Myeloma: Therapy, Excluding Transplantation: Poster II
3239 Efficacy of Lenalidomide Based Three Drug Versus Two Drug Regimen for Relapsed Multiple Myeloma: a Systematic Review and Meta-Analysis of Randomized Trials
Co-Author: Faiz Anwer, MD

3271 Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma After Lenalidomide-Based Treatment Failure
Co-Author: Christy J. Samaras, DO

3292 Efficacy and Safety of Daratumumab Based Regimens for Multiple Myeloma: a Systematic Review and Meta-Analysis
Co-Author: Faiz Anwer, MD

3309 Presentation Pattern, Diagnostic Markers, Management and Outcome of IgD Multiple Myeloma: a Systematic Review
Co-Author: Faiz Anwer, MD

Session 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II

3365 Comparative Effectiveness of Busulfan/Cyclophosphamide Versus Busulfan/Fludarabine Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
Presenter: Sagar S. Patel, MD
Co-Authors: Lisa Rybicki, MS; Arden Emrick; Victoria Winslow, RN; Jamie Starn, RN; Jamie Elberson, RN; Brittany Hodgeman, RN; Brad Pohlman, MD; Brian J. Bolwell, MD; Aaron T. Gerds, MD, MS; Betty K. Hamilton, MD; Rabi Hanna, MD; Matt Kalaycio, MD; Navneet S. Majhail, MD, MS; Ronald Sobecks, MD

Session 902. Health Services Research—Malignant Diseases: Poster II

3562 The Healthcare Burden of Emergency Department Utilization for Multiple Myeloma: a Five Years U.S Nationwide Study
Co-Author: Faiz Anwer, MD

Session 903. Outcomes Research—Non-Malignant Hematology: Poster II
3570 Deaths Due to Thrombotic Versus Bleeding Events Within 90 Days of Cancer Associated Thrombosis
Presenter: Mailey L. Wilks, MSN, APRN, NP-C
Co-Authors: Shyam K. Poudel, MD; Deborah Y. Park, BS; Xuefei Jia, MS; Vicki Pinkava, MSBS, PA-C; Meghan O’Brien, MS, ANP-BC; Barb Tripp, CNS; Jung-Min Song, RN, CNS; Keith R. McCrae, MD; Alok A. Khorana, MD; Dana E. Angelini, MD

Session 904. Outcomes Research—Malignant Conditions: Poster II
3600 Psychosocial Evaluation in Allogeneic Hematopoietic Cell Transplantation Recipients (Allo HCT): Psychosocial Assessment of Candidates for Transplant (PACT) as a Tool to Identify High-Risk Patients and Its Association with Transplant Outcomes
Co-Authors: Lisa Rybicki, MS; Jane Dabney, LISW-S; Christine Lawrence, LISW-S; Betty K. Hamilton, MD; Matt Kalaycio, MD; Linda McLellan, LISW; Ronald Sobecks, MD; Navneet S. Majhail, MD, MS

Monday, Dec. 3
6–8 p.m.
San Diego Convention Center, Hall GH
Session 331. Pathophysiology of Thrombosis: Poster III
3798 The Rate of Venous Thromboembolism in Cancer Patients Varies by Khorana Risk Category
Presenter: Alok A. Khorana, MD
Co-Author: Keith R. McCrae, MD

3799 Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism
Co-Authors: Keith R. McCrae, MD; Alok A. Khorana, MD
3800 Exosome Polyphosphate Mediates the Activation of FXII by Cancer Cell-Derived Exosomes
Presenter: Dewen You, PhD
Co-Authors: Suman Kundu, MBA; Alvin H. Schmaier, MD; Alok A. Khorana, MD; Keith R. McCrae, MD

Session 503. Clonal Hematopoiesis: Aging and Inflammation: Poster III
3840 Targeting NAD+ Modulating Enzymes to Improve HSC Function in Aging and Bone Marrow Failure
Presenter: Phillip J. Maciejewski
Co-Authors: Yihong Guan; Metis Hasipek, PhD; Anand D. Tiwari, PhD; Dale Grabowski, BS; James G. Phillips, PhD; Yogenthiran Saunthararajah, MD; Jaroslaw P. Maciejewski; Babal K. Jha

Session 508. Bone Marrow Failure: Poster III
3866 Heterozygous CTC1 Variants in Acquired Bone Marrow Failure
Presenter: Wenyi Shen, MD
Co-Authors: Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Reda Z. Mahfouz, MD, PhD; Tomas Radivoyevitch; Mohammad Fahad B. Asad; Jaroslaw P. Maciejewski, MD, PhD

3869 Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia
Presenter: Bhumika J. Patel, MD
Co-Authors: Shimoli Vipul Barot, MD; Bartlomiej P. Przychodzen; Teodora Kuzmanovic, BA; Michael Clemente, MS; Cassandra M. Hirsch; Valeria Visconte, PhD; Roy Souaid, MD; Marissa Versalle; Sarah S. Lee, MD; Tomas Radivoyevitch; Metis Haspiek; Aziz Nazha, MD; Matt Kalaycio, MD; Anjali S. Advani, MD; Hetty E. Carraway, MD, MBA; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

3871 The Shwachman-Diamond Syndrome Registry: Hematologic Complications
Co-Author: Rabi Hanna, MD

Session 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
3999 Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database
Co-Authors: Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

Session 614. Acute Lymphoblastic Leukemia: Therapy, Excluding Transplantation: Poster III
4031 Exploration of Potential Relationships Between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study
Co-Author: Anjali S. Advani, MD

Session 615. Acute Myeloid Leukemia: Commercially Available Therapy, Excluding Transplantation: Poster III
4040 Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort
Co-Authors: Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

Session 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Poster III

4067 Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia
Presenter: Metis Hasipek, PhD
Co-Authors: Dale Grabowski, BS; Yihong Guan; James G. Phillips, PhD; Jaroslaw P. Maciejewski, MD, PhD; Hetty E. Carraway, MD, MBA; Babal K. Jha

Session 623. Mantle Cell, Follicular and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
4146 Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival
Presenter: Allison M. Winter, MD
Co-Authors: Dhruvika Mukhija, MD; Deepa Jagadeesh, MD, MPH; Brian T. Hill, MD, PhD

4153 Intensive Induction Regimens After Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
Co-Authors: Yazeed Sawalha, MD; Brian T. Hill, MD, PhD

Session 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster III
4202 Risk of Post-Transplant Lymphoproliferative Disorders (PTLD) in Solid Organ Transplantation Patients with EBV Viremia
Presenter: Yazeed Sawalha, MD
Co-Authors: John McMichael, PhD; Lisa Rybicki, MS; Tamara A. Sussman, MD; Alex V. Mejia Garcia, MD; Robert M. Dean, MD; Brad Pohlman, MD; Brian T. Hill, MD, PhD; Deepa Jagadeesh, MD, MPH

Session 632. Chronic Myeloid Leukemia: Therapy: Poster III
4274 Poisson Regression Modeling of Chronic Myeloid Leukemia Mortality Trends
Presenter: Tomas Radivoyevitch
Co-Authors: Brian P. Hobbs, PhD; Jaroslaw P. Maciejewski, MD, PhD

Session 634. Myeloproliferative Syndromes: Clinical: Poster III
4282 Hepcidin Suppression by Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients
Co-Author: Aaron T. Gerds, MD, MS

4288 Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score
Co-Authors: Aaron T. Gerds, MD, MS; Ronald Sobecks, MD

Session 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III
4345 Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases
Presenter: Yihong Guan
Co-Authors: Anand D. Tiwari, PhD; Metis Hasipek, PhD; Dale Grabowski, BS; Yvonne Parker; Cassandra M. Hirsch; Amy C. Graham, BS, MS; Yasunobu Nagata; Bartlomiej P. Przychodzen; Aziz Nazha, MD; Daniel Lindner, MD, PhD; Tomas Radivoyevitch, PhD; James G. Phillips, PhD; Jaroslaw P. Maciejewski, MD, PhD; Babal K. Jha

4346 Modulation of TET2 Activity by Ascorbic Acid and Factors Affecting Lysine Acetylation
Presenter: Yihong Guan
Co-Authors: Edward F. Greenberg, MD; Metis Hasipek, PhD; Cassandra M. Hirsch; Amy C. Graham, BS, MS; Tomas Radivoyevitch, PhD; Valeria Visconte, PhD; Dewen You, PhD; Eiju Negoro, MD, PhD; Bartlomiej P. Przychodzen; Hideki Makishima, MD, PhD; Aziz Nazha, MD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD; Babal K. Jha

4350 SKI Controls MDS-Associated Chronic TGFb Signaling, Aberrant Splicing, and Stem Cell Fitness
Co-Author: Clemencia Colmenares, PhD
4351 Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS)
Presenter: Yasunobu Nagata
Co-Authors: Yihong Guan; Bartlomiej P. Przychodzen; Cassandra M. Hirsch; Teodora Kuzmanovic, BA; Tomas Radivoyevitch, PhD; Vera Adema, PhD; Hassan Awada, MD; Babal K. Jha; Rabi Hanna, MD; Thomas Laframboise, PhD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

4352 BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden
Co-Authors: Teodora Kuzmanovic, BA; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Yogenthiran Saunthararajah, MD; Hassan Awada, MD; Vera Adema, PhD; Amy C. Graham, BS, MS; Tomas Radivoyevitch, PhD; Hetty E. Carraway, MD, MBA; Aziz Nazha; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

4353 Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML
Presenter: Teodora Kuzmanovic
Co-Authors: Bhumika J. Patel, MD; Yasunobu Nagata; Hassan Awada, MD; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Sudipto Mukherjee, MD, PhD, MPH; Anjali S. Advani, MD; Aziz Nazha, MD; Aaron T. Gerds, MD, MS; Tomas Radivoyevitch, PhD; Hetty E. Carraway, MD, MBA; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

Session 637. Myelodysplastic Syndromes—Clinical Studies: Poster III
4370 Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance Between Local and Central Review in the NHLBI MDS Natural History Study
Co-Author: Mikkael A. Sekeres, MD, MS

4374 Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes
Co-Authors: John Barnard, PhD; Mikkael A. Sekeres, MD, MS

4389 Molecular Spectrum of CSF3R Variants Correlate with Specific Myeloid Malignancies and Secondary Mutations
Presenter: Vera Adema, PhD
Co-Authors: Cassandra M. Hirsch; Bartlomiej Przychodzen; Yasunobu Nagata; Tomas Radivoyevitch; Amy C. Graham, BS, MS; Louis Williams, MD, MBA; Hassan Awada, MD; Aziz Nazha; Hetty E. Carraway, MD, MBA; Hrishikesh M. Mehta, PhD; Mikkael A. Sekeres, MD, MS; Valeria Visconte, PhD; Rabi Hanna, MD; Seth J. Corey, MD; Jaroslaw P. Maciejewski, MD, PhD

Session 641. CLL: Biology and Pathophysiology, Excluding Therapy: Poster III
4410 Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings
Co-Authors: Brian T. Hill, MD, PhD; Allison M. Winter, MD

4414 Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States
Co-Author: Brian T. Hill, MD, PhD

Session 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III
4603 Risk Factors for Early Relapse After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
Presenter: Sagar S. Patel, MD
Co-Authors: Betty K. Hamilton, MD; Lisa Rybicki, MS; Dawn Thomas; Arden Emrick; Aziz Nazha; Sudipto Mukherjee, MD, PhD, MPH; Anjali S. Advani, MD; Hetty E. Carraway, MD, MBA; Brad Pohlman, MD; Brian J. Bolwell, MD; Robert M. Dean, MD; Aaron T. Gerds, MD, MS; Rabi Hanna, MD; Matt Kalaycio, MD; Aiwen Zhang, PhD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD; Navneet S. Majhail, MD, MS; Ronald Sobecks, MD

Session 901. Health Services Research—Non-Malignant Conditions: Poster III
4695 National Trends in Leukemia Related Emergency Department Visits, Health Care Burden and Disposition Rate in the United States, 2010-2014
Co-Author: Faiz Anwer, MD

Session 902. Health Services Research—Malignant Diseases: Poster III
4731 Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Disease Registry
Co-Author: Mikkael A. Sekeres, MD, MS

4736 Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect® MDS/AML Disease Registry
Presenter: Sudipto Mukherjee, MD, PhD, MPH

4755 Early Infectious Complications after Autologous Hematopoietic Cell Transplantation (AHCT) for Lymphoma
Presenter: Shafia Rahman, MD
Co-Authors: Lisa Rybicki, MS; Eric Cober, MD; Robert M. Dean, MD; Betty K. Hamilton, MD; Deepa Jagadeesh, MD, MPH; Brian T. Hill, MD, PhD; Brad Pohlman, MD; Ronald Sobecks, MD; Matt Kalaycio, MD; Sherif Mossad, MD; Navneet S. Majhail, MD

4759 Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: a Multicenter Study
Co-Authors: Brian T. Hill, MD, PhD; Allison M. Winter, MD

4768 Adolescent and Young Adult (AYA) Hematopoietic Cell Transplantation (HCT) Recipients Have Similar Quality of Life (QoL) Compared to Older Adults in the First Year Post-Transplantation
Presenter: Reema R. Mathanda, MD
Co-Authors: Betty K. Hamilton, MD; Lisa Rybicki, MS; Anjali S. Advani, MD; Brian J. Bolwell, MD; Amy Colver, LISW; Jane Dabney, LISW-S; Christina Ferraro, CNP; Aron Flagg, MD; Rabi Hanna, MD; Matt Kalaycio, MD; Christine Lawrence, LISW-S; Linda McLellan, LISW; Ronald Sobecks, MD; Navneet S. Majhail, MD, MS

4802 Cost and Value Analysis of Standard Versus Rapid Daratumumab Infusion in Multiple Myeloma
Presenter: Sarah S. Lee, MD
Co-Authors: Nathaniel Rosko, PharmD; Pramod Pinnamaneni, MD; Craig Savage; Alex V. Mejia Garcia, MD; Christy J. Samaras, DO; and Jason Valent, MD

Session 903. Outcomes Research—Non-Malignant Hematology: Poster III
4805 Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis
Presenter: Madeline Waldron, PharmD
Co-Authors: Caitlin Siebenaller, PharmD; Brian P. Hobbs, PhD; Marc Earl, PharmD; Mary Schleicher; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Aziz Nazha, MD; Aaron T. Gerds, MD, MS; Betty K. Hamilton, MD; Ronald Sobecks, MD; Matt Kalaycio, MD; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

4806 Impact of Venous Thromboembolism During High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay
Presenter: Madeline Waldron, PharmD
Co-Authors: Caitlin Siebenaller, PharmD; Marc Earl, PharmD; Xuefei Jia, MS; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Aziz Nazha, MD; Aaron T. Gerds, MD, MS; Betty K. Hamilton, MD; Ronald Sobecks, MD; Matt Kalaycio, MD; Barb Tripp, CNS; Brian P. Hobbs, PhD; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

4809 Clinical Outcomes of Isolated Distal Deep Vein Thrombosis Associated with Cancer: the Cleveland Clinic Experience
Presenter: Shyam K. Poudel, MD
Co-Authors: Xuefei Jia, MS; Deborah Y. Park, BS; Mailey Lynn Wilks, CNP, MSN, APRN; Vicki Pinkava, MSBS, PA-C; Meghan O’Brien, MS, ANP-BC; Barbara Tripp, CNS, AOCN; Jung-Min Song, RN, CNS; Keith R. McCrae, MD; Alok A. Khorana, MD; Dana E. Angelini, MD

Session 904. Outcomes Research—Malignant Conditions: Poster III
4832 Patient-Reported Outcomes in Systemic Light-Chain Amyloidosis
Presenter: Rajshekhar Chakraborty, MBBS
Co-Authors: Lisa Rybicki, MS; Christy J. Samaras, DO; Beth M. Faiman, PhD, CNP; Jason Valent, MD; Navneet S. Majhail, MD, MS

4835 Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: a Systemic Review and Meta-Analysis
Presenter: Rajshekhar Chakraborty, MBBS
Co-Authors: Naimisha Marneni; Alex V. Mejia Garcia, MD; Faiz Anwer, MD; Alok A. Khorana, MD; Navneet S. Majhail, MD, MS

Related Articles

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

Ad